Increasing Transparency in Generic Drug Applications Act

Bill Number: S. 1302
Origin Chamber: Senate
Congress: 119th Congress, Session 1
Policy Area: Health
Status: Introduced
Latest Action: 2025-04-03: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Last Updated: 2026-02-05T17:34:10Z

AI-Generated Summary

Summary of S. 1302: Increasing Transparency in Generic Drug Applications Act

Purpose

This bill aims to improve transparency in the approval process for generic drugs by requiring the U.S. Food and Drug Administration (FDA) to provide clearer information about whether a proposed generic drug matches the brand-name (listed) drug in terms of its inactive ingredients—the non-active components that help deliver the medicine, such as fillers or preservatives. The goal is to help generic drug developers understand similarities and differences more easily, potentially speeding up the creation of affordable alternatives to brand-name drugs.

Key Provisions

Requests for Information: Generic drug applicants (or those planning to apply) can request, through formal correspondence with the FDA, confirmation on whether their drug is qualitatively (same types of ingredients) and quantitatively (same amounts/concentrations) identical to the brand-name drug, focusing on inactive ingredients. The FDA must respond and can also provide this info proactively during reviews.
Disclosure if Not Identical: If the drugs differ, the FDA must identify the differing ingredients and, for any concentration differences, specify the exact deviation (e.g., how much more or less of an ingredient).
Stability of Determinations: If the FDA confirms the drugs are identical, it cannot later reverse this unless the brand-name drug's formula changes due to safety or effectiveness issues, or an error is found. In the error case, the FDA must notify the applicant in writing.
Legal Protections for Disclosures: These revelations are legally allowed and do not count as unauthorized leaks of confidential info. However, they do not change the protected status of trade secrets (proprietary business information) under existing laws.
FDA Guidance Requirement: Within one year of enactment, the FDA must issue (or update) draft guidance explaining how it will assess qualitative and quantitative sameness, including for pH adjusters (substances that control acidity). This involves a public comment period of at least 60 days, followed by final guidance within another year.
Effective Date: The new rules apply immediately upon the bill becoming law, even before the guidance is finalized.

Significant Changes to Existing Law

Amends Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which governs abbreviated new drug applications (ANDAs) for generics, by adding a new subparagraph (H).
Previously, the FDA had no mandatory requirement to disclose specific details about inactive ingredient matches or differences upon request, leading to potential uncertainty for generic developers. This adds enforceable transparency without broadly exposing confidential data.

Potential Impacts

Government Agencies: The FDA (under the Department of Health and Human Services) will face increased administrative duties, such as handling more requests and developing guidance, which could strain resources but promote more efficient reviews.
Citizens: Patients and consumers may benefit from faster generic drug approvals, increasing access to lower-cost medications and reducing reliance on expensive brand-name drugs.
International Relations: Minimal direct impact, though it could indirectly support U.S. generic drug exports by streamlining domestic development, potentially affecting global pharmaceutical trade.
Overall, it may accelerate generic competition, lowering drug prices without compromising safety.

Main Stakeholders Affected

Generic Drug Manufacturers: Primary beneficiaries, gaining clearer FDA feedback to refine products and avoid approval delays.
Brand-Name Drug Manufacturers: Their trade secrets remain protected, but they may see quicker generic entry into the market, potentially reducing their revenue from exclusivities.
FDA and Regulators: Must implement new processes, balancing transparency with confidentiality.
Patients and Healthcare Providers: Indirectly affected through improved access to affordable generics.
Bipartisan Sponsors: Introduced by Senators Hassan, Paul, Hickenlooper, and Lee, indicating cross-party support for drug affordability.

Notable Legal, Constitutional, or Political Implications

Legal: Reinforces existing trade secret protections under laws like the Trade Secrets Act (18 U.S.C. § 1905) and Freedom of Information Act exemptions, while authorizing targeted disclosures to avoid litigation over confidentiality. No broad waiver of proprietary rights.
Constitutional: No apparent challenges; it aligns with Congress's authority to regulate interstate commerce and public health under the Commerce Clause, without infringing on due process or property rights.
Political: Promotes drug price reduction—a bipartisan priority—by addressing "transparency gaps" in generics without overhauling the FDA's core framework. Could influence future pharma policy debates on competition and innovation.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Hassan, Margaret Wood [D-NH]

Cosponsors (6)

Sen. Paul, Rand [R-KY], Sen. Hickenlooper, John W. [D-CO], Sen. Lee, Mike [R-UT], Sen. Lankford, James [R-OK], Sen. Ossoff, Jon [D-GA], Sen. Husted, Jon [R-OH]

Recent Actions

2025-04-03: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2025-04-03: Introduced in Senate

Bill Versions

Increasing Transparency in Generic Drug Applications Act — issued 2025-04-03 — PDF (5 pages)